Tallac Therapeutics is harnessing the power of both the innate and adaptive immune system to develop cancer therapeutics. Antibody drug conjugates (ADCs) couple the specificity of antibodies with functional payloads that can be used to trigger events within the body. Tallac is building a pipeline of oligonucleotide-based ADC candidates including novel Toll-like Receptor Agonist Antibody Conjugates (TRAACs) to systematically deliver a potent Toll-like receptor agonist and trigger immune activation within the tumor microenvironment. Tallac currently has two TRAAC programs in clinical development.

Tallac Therapeutics

Founded: 2018
Location: Burlingame, CA
Employee range: 11 - 50
Clinical stage: Clin0
Therapy area: Solid tumors
Drug types: ONC
Lead product: TAC-001
Funding: $62M A Dec 2020

Drug notes:

About:

Jobs: